A single-center, retrospective and observational study of vedolizumab in crohn's disease (CD) and ulcerative colitis (UC) patients.
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2018
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 16 Jul 2018 New trial record
- 16 Jun 2018 Results (n=171) treated with vedolizumab from July 14 to July 2017 were presented at the 19th Annual Congress of the European League Against Rheumatism.